[18F]-JK-PSMA-7 and [18F]-FDG tumour PET uptake in treated xenograft human prostate cancer model in mice
Authors:
- Gaetan Van SimaeysGSGaetan Van Simaeys
- Gilles DoumontGDGilles Doumont
- Coraline De MaeseneireCMCoraline De Maeseneire
- Nicolas PassonNPNicolas Passon
- Simon LacroixSLSimon Lacroix
- Cédric LentzCLCédric Lentz
- Arnaud HorionAHArnaud Horion
- Corentin WarnierCWCorentin Warnier
- David TorresDTDavid Torres
- Corentin MartensCMCorentin Martens
- Irina VierasuIVIrina Vierasu
- Dominique EgriseDEDominique Egrise
- 4 January 2021
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 48 (6) , 1773-1784
Abstract
Purpose This preclinical study aims to evaluate the extent to which a change in prostate-specific membrane antigen (PSMA) expression of castration-resistant prostate cancer (CRPC) following standard treatment is reflected in [18F]JK-PSMA-7 PET/CT. Methods Castrated mice supplemented with testosterone implant were xenografted with human LNCaP CRPC. After appropriate tumour growth, androgen deprivation therapy (ADT) was carried out by the removal of the implant followed by a single injection of docetaxel (400 μg/20-g mouse) 2 weeks later. [18F]JK-PSMA-7 PET/CT were performed before ADT, then before and at days 12, 26, 47 and 69 after docetaxel administration. The [18F]JK-PSMA-7 PET data were compared to corresponding unspecific metabolic [18F]FDG PET/CT and ex vivo quantification of PSMA expression estimated by flow cytometry on repeated tumour biopsies. Results ADT alone had no early effect on LNCaP tumours that pursued their progression. Until day 12 post-docetaxel, the [18F]JK-PSMA7 uptake was significantly higher than that of [18F]FDG, indicating the persistence of PSMA expression at those time points. From day 26 onwards when the tumours were rapidly expanding, both [18F]JK-PSMA7 and [18F]FDG uptake continuously decreased although the decrease in [18F]JK-PSMA uptake was markedly faster. The fraction of PSMA-positive cells in tumour biopsies decreased similarly over time to reach a non-specific level after the same time period. Conclusion Applying PSMA-based imaging for therapy monitoring in patients with CRPC should be considered with caution since a reduction in [18F]JK-PSMA-7 PET uptake after successive ADT and chemotherapy may be related to downregulation of PSMA expression in dedifferentiated and rapidly proliferating tumour cells.Keywords
Funding Information
- Walloon Region (C-7559)
- Walloon Region (C-7559)
- ERDF
- Fondation ULB
- Fonds Erasme
- Association Vinçotte Nuclear
- Fonds pour la Formation à la Recherche dans l’Industrie et dans l’Agriculture (5120417F)
This publication has 40 references indexed in Scilit:
- New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamideEuropean Journal of Nuclear Medicine and Molecular Imaging, 2020
- Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with 68Ga-PSMA-11 PET/MRI in men with treatment-naïve prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019
- The effect of androgen deprivation therapy on 68Ga-PSMA tracer uptake in non-metastatic prostate cancer patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019
- EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)European Journal of Nuclear Medicine and Molecular Imaging, 2019
- Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial 68Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen BlockadeJournal of Nuclear Medicine, 2018
- Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2018
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate CancerEuropean Urology, 2017
- 68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human ExperienceJournal of Nuclear Medicine, 2016
- Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapyEJNMMI Research, 2015
- Upregulation of prostate-specific membrane antigen after androgen-deprivation therapyUrology, 1996